Company Update: Actavis plc (NYSE:ACT) – Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline

[PR Newswire] – DUBLIN, Sept. 2, 2014 /PRNewswire/ — Actavis plc (ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis’ New Drug Application (NDA) for eluxadoline, . . . → Read More: Company Update: Actavis plc (NYSE:ACT) – Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline Similar Articles: Company Update (NYSE:ACT): Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 Market Update (NYSE:ACT): Actavis Confirms Generic Neupro® Patent Challenge Company Update (NYSE:ACT): Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI)